SUMMARY
Meningiomas arising from the meningothelial central nervous system lining are the most common primary intracranial tumors, and a significant cause of neurologic morbidity and mortality1. There are no effective medical therapies for meningioma patients2,3, and new treatments have been encumbered by limited understanding of meningioma biology. DNA methylation profiling provides robust classification of central nervous system tumors4, and can elucidate targets for molecular therapy5. Here we use DNA methylation profiling on 565 meningiomas integrated with genetic, transcriptomic, biochemical, and single-cell approaches to show meningiomas are comprised of 3 epigenetic groups with distinct clinical outcomes and biological features informing new treatments for meningioma patients. Merlin-intact meningiomas (group A, 34%) have the best outcomes and are distinguished by a novel apoptotic tumor suppressor function of NF2/Merlin. Immune-enriched meningiomas (group B, 38%) have intermediate outcomes and are distinguished by immune cell infiltration, HLA expression, and lymphatic vessels. Hypermitotic meningiomas (group C, 28%) have the worst outcomes and are distinguished by convergent genetic mechanisms misactivating the cell cycle. Consistently, we find cell cycle inhibitors block meningioma growth in cell culture, organoids, xenografts, and patients. Our results establish a framework for understanding meningioma biology, and provide preclinical rationale for new therapies to treat meningioma patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the UCSF Wolfe Meningioma Program Project and NIH grants F30CA246808 and T32GM007618 to A.C.; NIH grant P50CA097257 to J.J.P.; the UCSF Wolfe Meningioma Program Project and NIH grant F32CA213944 to S.T.M.; the UCSF Wolfe Meningioma Program Project to C.D.E., J.E.V-M., H.N.V., S.E.B., N.A.O.B., J.S., and N.B.; and the UCSF Physician Scientist Scholar Program, the UCSF Wolfe Meningioma Program Project, and NIH grant K08CA212279 to D.R.R.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board (IRB) at the University of California, San Francisco (UCSF) reviews all research that involves human subjects performed by UCSF faculty, staff, or students or researchers at UCSF-affiliated institutions before the research can begin. The IRB operates under federal regulations, state laws and institutional policy to review research involving human subjects to ensure the ethical and equitable treatment of those subjects.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data generated from the research project will be made as widely and freely available as possible while safeguarding the privacy of subjects and protecting confidentiality. As per the NIH Genomic Data Sharing Policy NOT-OD-14-124, the large-scale human genomic data and relevant associated data generated by this research will be submitted to an NIH-designated data repository no later than 6 months after initial data submission for publication, or at the time of acceptance of first publication, whichever occurs first.
